期刊
NATURE CELL BIOLOGY
卷 24, 期 3, 页码 384-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41556-022-00850-x
关键词
-
类别
资金
- UNC Lineberger Comprehensive Cancer Center Core Support Grant [P30-CA016086]
- US National Institutes of Health [R01CA218600, R01CA268519, R01CA211336, R01CA215284, R01CA230854, R01GM122749]
- Kimmel Scholar Award
- Gabrielle's Angel Foundation for Cancer Research
- When Everyone Survives (WES) Leukemia Research Foundation
- UNC Lineberger Cancer Center UCRF Stimulus Initiative grants
- National Institutes of Health SIG grants [1S10OD025132, 1S10OD028504]
The study reveals the noncanonical oncogenic roles of EZH2 in acute leukaemia, demonstrating its additional functions in binding cMyc and activating gene expression. To target the multifaceted tumorigenic functions of EZH2, the researchers developed a degrader, MS177, which effectively depletes both canonical and noncanonical complexes of EZH2 and shows a faster and more potent effect in suppressing cancer growth.
Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3 deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 has additional noncanonical functions by binding cMyc at non-PRC2 targets and uses a hidden transactivation domain (TAD) for (co)activator recruitment and gene activation. Both canonical (EZH2-PRC2) and noncanonical (EZH2-TAD-cMyc-coactivators) activities of EZH2 promote oncogenesis, which explains the slow and ineffective antitumour effect of inhibitors of the catalytic function of EZH2. To suppress the multifaceted activities of EZH2, we used proteolysis-targeting chimera (PROTAC) to develop a degrader, MS177, which achieved effective, on-target depletion of EZH2 and interacting partners (that is, both canonical EZH2-PRC2 and noncanonical EZH2-cMyc complexes). Compared with inhibitors of the enzymatic function of EZH2, MS177 is fast-acting and more potent in suppressing cancer growth. This study reveals noncanonical oncogenic roles of EZH2, reports a PROTAC for targeting the multifaceted tumorigenic functions of EZH2 and presents an attractive strategy for treating EZH2-dependent cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据